Medicare Enrolled

Dr. Douglas Scherr, MD

Urology Physician · New York, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
525 E 68TH ST # 94, New York, NY 10021
2127465465
In practice since 2006 (19 years)
NPI: 1114014206 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Scherr from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Scherr? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Scherr

Dr. Douglas Scherr is an urology physician in New York, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Scherr performed 16,546 Medicare services across 2,376 unique beneficiaries.

Between the years covered by Open Payments, Dr. Scherr received a total of $9,025 from 7 pharmaceutical and/or device companies across 32 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Scherr is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 5% volume in NY $9,025 industry payments

Medicare Practice Summary

Medicare Utilization ↗
16,546
Medicare services
Top 5% in NY for urology physician
2,376
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~871 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
BCG treatment for bladder cancer 13,308 $2 $11
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
992 $8 $20
Cystourethroscopy
A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract.
565 $214 $1,800
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
354 $77 $279
Bladder instillation of anti-cancer drug
A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue.
279 $80 $1,600
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
270 $113 $394
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
134 $145 $552
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
66 $151 $550
Imaging of urinary tract with contrast
An imaging test of the urinary tract performed after a contrast agent is injected to enhance visibility of the structures.
61 $22 $365
New patient office visit, complex (60-74 min) 61 $195 $690
Endoscopic destruction of bladder/urethra growth, less than 0.5 cm
A procedure to remove abnormal tissue growths from the bladder or urethra using an endoscope. This specific code applies when the growths are smaller than 0.5 centimeters.
59 $721 $5,645
Bladder tumor removal via endoscope
This procedure involves using an endoscope to destroy or remove a large growth from the bladder.
56 $359 $5,100
Ureteral stent insertion via endoscope
A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder.
52 $100 $2,725
Surgical removal of prostate and lymph nodes
This procedure involves the surgical removal of the prostate gland and surrounding lymph nodes using an endoscope.
43 $873 $14,000
Endoscopic removal of pelvic lymph nodes, bilateral
A surgical procedure to remove lymph nodes from both sides of the pelvis using an endoscope. This minimally invasive technique involves making small incisions to access and excise the tissue.
37 $309 $5,000
Endoscopic removal of bladder or urethra growth, 2.0-5.0 cm
This procedure uses an endoscope to destroy or remove a growth from the bladder or urethra that measures between 2.0 and 5.0 centimeters.
36 $264 $3,700
Endoscopic removal of foreign body, stone, or stent from urethra or bladder
A procedure to remove a foreign object, stone, or stent from the urethra or bladder using an endoscope. The endoscope is a thin tube with a camera inserted into the urinary tract to locate and extract the item.
28 $291 $2,100
Suture suspension of urethra to control leakage using an endoscope
A surgical procedure that uses an endoscope to place sutures that suspend the urethra in order to control urinary leakage.
26 $346 $4,515
Urinalysis with microscopic exam
A urine test performed manually that includes examining the sample under a microscope to check for abnormalities.
25 $3 $20
Bladder/urethra growth removal via endoscope, 0.5-2.0 cm
This procedure uses an endoscope to destroy or remove a growth from the bladder or urethra that measures between 0.5 and 2.0 centimeters.
24 $216 $2,500
Cystourethroscopy with ureteroscopy or pyeloscopy
A diagnostic procedure using an endoscope to examine the bladder, urethra, and ureter or kidney.
20 $274 $3,200
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
20 $50 $180
Radical cystectomy with lymph node removal and urinary diversion
Surgical removal of the bladder and pelvic lymph nodes, with rerouting of the ureters to the intestine to create a new opening for urine drainage.
15 $2,014 $25,000
Ureter or kidney growth biopsy or destruction via endoscope
A procedure to remove or destroy a growth in the ureter or kidney using an endoscope. The endoscope is a thin, lighted tube inserted into the body to visualize and treat the area.
15 $380 $4,600
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.5% high complexity
0.5% medium
99.1% routine

Industry Payment Transparency

Open Payments through 2023 ↗
$9,025
Total received (2019-2023)
Avg $2,256/year across 4 years
Top 20% in NY for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
7
Companies
32
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$7,314 (81.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,074 (11.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$637 (7.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2023
$205
2022
$2,293
2020
$6,299
2019
$228

Payments by company (2023)

Consulting
Speaking
Meals & Travel
Research
UroGen Pharma, Inc.
$134
PFIZER INC.
$32
Coloplast Corp
$32
Intuitive Surgical, Inc.
$6
Top 3 companies account for 96.8% of 2023 payments
All-time payments by company (2019-2023) ›
Intuitive Surgical, Inc.
$7,321
AstraZeneca UK Limited
$1,074
UroGen Pharma, Inc.
$216
PFIZER INC.
$167
EDAP TECHNOMED INC
$121
Astellas Pharma US Inc
$94
Coloplast Corp
$32
Top 3 companies account for 95.4% of all-time payments
Associated products mentioned in payments ›
DA VINCI SP · Da Vinci Surgical System · JELMYTO · SpeediCath · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (81%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware.

Looking for an urology physician in New York?
Compare urology physicians in the New York area by procedure volume, costs, and industry payment transparency.
Browse urology physicians nearby

Geographic Context

Urology physicians within 10 mi
733
Per 100K population
45.0
County median income
$104,553
Nearest hospital
HOSPITAL FOR SPECIAL SURGERY
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2023
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Scherr is a mixed practice specialist, with above-average Medicare volume (top 5% in NY), with speaking/promotional industry engagement in the top 20% of NY peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Scherr experienced with bcg treatment for bladder cancer?
Based on Medicare claims data, Dr. Scherr performed 13,308 bcg treatment for bladder cancer services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Scherr receive payments from pharmaceutical companies?
Yes. Dr. Scherr received a total of $9,025 from 7 companies across 32 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Scherr's costs compare to other urology physicians in New York?
Dr. Scherr's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Scherr) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →